WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Biocant - Technology Transfer Association
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Webinar
MEDTECH
GATC Health Corp | April 22, 2022
GATC Health, a biotech company that uses artificial intelligence and advanced multiomics to revolutionize drug discovery and disease prediction, announced that it filed a patent application for an innovative new prodrug designed to safely cross the blood-brain barrier (BBB) for cancer treatment. GATC Health's entry into the oncology drug discovery market is marked by this breakthrough, which was made possible by the company's innovative Multiomics Advanced TechnologyTM AI platform....
CELL AND GENE THERAPY
ElevateBio | November 25, 2021
ElevateBio, LLC, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, announced that the United States Patent and Trademark Office has issued US Patent No. 11,162,114 with an anticipated expiry date of June 23, 2040, inclusive of 384 days of patent term adjustment . This patent, issued to LifeEDIT Therapeutics, Inc. is the first to provide composition and methods of use protection for various RNA-guided nucleases in Life Edit’s gene editing...
MEDICAL
Light Bio | April 18, 2022
Light Bio, Inc., a company that is creating bioluminescent plants for home and garden, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration to leverage Ginkgo's plant cell assays for bioluminescence engineering. Through the agreement, Ginkgo aims to help improve the luminescent output and efficiency of the enzymes within Light Bio's glowing ornamental plants. The scientists at Light Bio have discovered a new...
BioTech Life Sciences | August 06, 2020
BioTech Life Sciences (BioTech – https://btl.science) recently announced it was studying the effects of its proprietary formulas on long-term patient symptoms related to COVID-19 Post-Viral Fatigue (long-haulers) and chronic fatigue syndrome (C.F.S.).The findings will be a part of a larger research study undertaken by the company, and is currently calling for voluntary participants; especially those who suffer from myalgic encephalomyelitis (M.E.), chronic fatigue syndrome, or Post-V...
INDUSTRIAL IMPACT, MEDICAL
Whitepaper
RESEARCH
Video
Article
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE